Profil bibliographique

Ahmad A. Tarhini

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

796Publications signalées

15602Citations signalées

2Affiliations récentes

Institutions déclarées

Moffitt Cancer Center Advanced Dermatology

Domaines associés

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy researchCutaneous Melanoma Detection and ManagementRadiomics and Machine Learning in Medical Imaging

Publications récentes

Accès ouvert 2026 preprintOpenAlex

BCL11B targeting in tumor CD8 + T cells amplifies anti-tumor response by blocking exhaustion while promoting stemness and cytotoxicity

Leonardo Silvane, Τόμας Ζελένκα, Divya P. Talada, Valeriu B. Cismasiu et autres

0 citationsbioRxiv (Cold Spring Harbor Laboratory)

2026 articleOpenAlex

Evidence of genetic susceptibility to immune-related dermatitis in patients with melanoma treated with immune checkpoint inhibitors

Ahmad A. Tarhini, Mohammad Ali Khaksar, Zhihua Chen, Sandra J. Lee et autres

0 citationsMelanoma Research

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplemental Figure 4 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Joseph Markowitz, Michael Shamblott, Andrew S. Brohl, Amod A. Sarnaik et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplemental Figure 1 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Joseph Markowitz, Michael Shamblott, Andrew S. Brohl, Amod A. Sarnaik et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplemental Figure 5 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Joseph Markowitz, Michael Shamblott, Andrew S. Brohl, Amod A. Sarnaik et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplemental Figure 6 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Joseph Markowitz, Michael Shamblott, Andrew S. Brohl, Amod A. Sarnaik et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplemental Figure 8 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Joseph Markowitz, Michael Shamblott, Andrew S. Brohl, Amod A. Sarnaik et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplemental Table 1 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Joseph Markowitz, Michael Shamblott, Andrew S. Brohl, Amod A. Sarnaik et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplemental Figure 3 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Joseph Markowitz, Michael Shamblott, Andrew S. Brohl, Amod A. Sarnaik et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplemental Figure 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Joseph Markowitz, Michael Shamblott, Andrew S. Brohl, Amod A. Sarnaik et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplemental Table 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Joseph Markowitz, Michael Shamblott, Andrew S. Brohl, Amod A. Sarnaik et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplemental Figure 7 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Joseph Markowitz, Michael Shamblott, Andrew S. Brohl, Amod A. Sarnaik et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.